Skip to content

Trevi Therapeutics, Inc. TRVI Cash Provided by (Used in) Operating Activity, Including Discontinued Operation

Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies

Travel + Leisure logo
Travel + LeisureTNL
$38M-68.6%
Unifirst logo
UnifirstUNF
$73.62M+4.9%
PennyMac Financial Services, Inc. logo
PennyMac Financial Services, Inc.PFSI
-$1.34B-226%
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
-$3.3M-1,200%
Archer Aviation logo
Archer AviationACHR
-$149.1M-57.6%
Repligen logo
RepligenRGEN
$28.3M+88.6%

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K
Free cash flow-$16.8M

Valuation

See full
Market cap$2.49B+152%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0.0×
Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trevi Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Trevi Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation?
Trevi Therapeutics, Inc. (TRVI) reported cash provided by (used in) operating activity, including discontinued operation of -$16.69M in Q1 2026.
How has Trevi Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
Trevi Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation decreased by 23.8% year-over-year, from -$13.48M to -$16.69M.
What is the long-term trend for Trevi Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation?
Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation has grown at a 9.8% compound annual growth rate (CAGR), from -$28.95M to -$42.09M.
What does cash provided by (used in) operating activity, including discontinued operation mean?
Measures the cash generated from the company's core business operations, excluding financing and investing activities. It reflects the ability of the company to convert revenue into actual cash flow after accounting for changes in working capital.